ATE429487T1 - Lutzomyia longipalpis-polypeptide und verwendungsverfahren - Google Patents

Lutzomyia longipalpis-polypeptide und verwendungsverfahren

Info

Publication number
ATE429487T1
ATE429487T1 AT03781500T AT03781500T ATE429487T1 AT E429487 T1 ATE429487 T1 AT E429487T1 AT 03781500 T AT03781500 T AT 03781500T AT 03781500 T AT03781500 T AT 03781500T AT E429487 T1 ATE429487 T1 AT E429487T1
Authority
AT
Austria
Prior art keywords
disclosed
polypeptides
lutzomyia longipalpis
longipalpis
longipalpis polypeptides
Prior art date
Application number
AT03781500T
Other languages
English (en)
Inventor
Jesus Valenzuela
Jose Ribeiro
Aldina Barral
Manoel Netto
Claudia Brodskyn
Regis Gomes
Original Assignee
Us Gov Health & Human Serv
Fundacao Oswaldo Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, Fundacao Oswaldo Cruz filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE429487T1 publication Critical patent/ATE429487T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0003—Invertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Insects & Arthropods (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03781500T 2002-10-29 2003-10-29 Lutzomyia longipalpis-polypeptide und verwendungsverfahren ATE429487T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42230302P 2002-10-29 2002-10-29
PCT/US2003/034453 WO2004039958A2 (en) 2002-10-29 2003-10-29 Lutzomyia longipalpis polypeptides and methods of use

Publications (1)

Publication Number Publication Date
ATE429487T1 true ATE429487T1 (de) 2009-05-15

Family

ID=32230337

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03781500T ATE429487T1 (de) 2002-10-29 2003-10-29 Lutzomyia longipalpis-polypeptide und verwendungsverfahren

Country Status (10)

Country Link
US (6) US7485306B2 (de)
EP (2) EP1572968B1 (de)
JP (2) JP2006516187A (de)
AT (1) ATE429487T1 (de)
AU (1) AU2003287267A1 (de)
BR (1) BR0315872A (de)
DE (1) DE60327366D1 (de)
ES (1) ES2447843T3 (de)
MX (1) MXPA05004714A (de)
WO (1) WO2004039958A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05003049A (es) 2002-09-19 2005-11-17 Us Gov Health & Human Serv Polipeptidos de phlebotomus ariasi, polipeptidos de phlebotomus perniciosus y metodos de uso.
MXPA05004714A (es) 2002-10-29 2006-03-17 Us Gov Health & Human Serv Polipeptidos de lutzomyia longipalpis y metodos de uso.
US8968749B2 (en) 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
BRPI0603490B1 (pt) * 2006-07-21 2018-04-24 Universidade Federal De Minas Gerais Vacina recombinante contra a leishmaniose visceral canina
GB0717864D0 (en) * 2007-09-13 2007-10-24 Peptcell Ltd Peptide sequences and compositions
MX348137B (es) * 2008-05-08 2017-05-29 Merial Ltd Vacuna de la leishmaniasis con el uso del inmunogeno salival de la mosca de la arena.
WO2010021940A1 (en) * 2008-08-18 2010-02-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Insect proteins as adjuvants to accelerate the immune response
JP5590986B2 (ja) 2010-06-23 2014-09-17 株式会社シマノ 釣り用リールのワンウェイクラッチ
AR111842A1 (es) 2017-06-02 2019-08-21 Amgen Inc Antagonistas de péptido pac1

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4444487A (en) 1979-07-02 1984-04-24 Xerox Corporation Multiple-flash fuser
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (de) 1984-08-24 1991-10-09 The Upjohn Company Rekombinante DNA-Verbindungen und Expression von Polypeptiden wie tPA
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
EP0256654B1 (de) 1986-07-07 1996-09-18 Centocor, Inc. Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB2197321B (en) 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
IE872748L (en) 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
JP2955759B2 (ja) 1988-07-20 1999-10-04 セゲブ・ダイアグノスティックス・インコーポレイテッド 核酸配列を増幅及び検出する方法
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5397772A (en) 1989-06-29 1995-03-14 The President And Fellows Of Harvard College Vasodilatory peptides from the salivary gland of the sand fly Lutzomyia longipalpis
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5427930A (en) 1990-01-26 1995-06-27 Abbott Laboratories Amplification of target nucleic acids using gap filling ligase chain reaction
SG46445A1 (en) 1990-01-26 1998-02-20 Immunomedics Inc Vaccines against cancer and infectious diseases
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US5709860A (en) 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
WO1993001831A1 (en) 1991-07-25 1993-02-04 Idec Pharmaceuticals Corporation Induction of cytotoxic t-lymphocyte responses
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
DE69332485T2 (de) 1992-08-11 2003-11-13 The President And Fellows Of Harvard College, Cambridge Immunmodulierende peptide
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
AU7529194A (en) 1993-09-03 1995-03-22 Mcgill University Differentially expressed (leishmania) genes and proteins
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5529780A (en) 1994-03-30 1996-06-25 Virogenetics Corporation Nucleotide and amino acid sequences of canine herpesvirus gB and gC
US5648211A (en) 1994-04-18 1997-07-15 Becton, Dickinson And Company Strand displacement amplification using thermophilic enzymes
DE69524105T2 (de) 1994-07-15 2002-07-18 Organon Teknika B.V., Boxtel Verwendung von rna-polymerase zur verbesserung von nukeinsaeure-amplifikationsverfahren
CA2214029A1 (en) 1995-04-25 1996-10-31 Magda Marquet Single-vial formulations of dna/lipid complexes
AT402203B (de) 1995-06-13 1997-03-25 Himmler Gottfried Dipl Ing Dr Verfahren zur transkriptionsfreien amplifizierung von nucleinsäuren
EP0803573A1 (de) 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronische Expressionskonstrukt mit Cytokinen für multivalente Impstoffe
FR2750865B1 (fr) 1996-06-27 1998-12-04 Rhone Merieux Vaccin vivant recombinant a base d'herpesvirus canin, notamment contre la maladie de carre, la rage ou le virus parainfluenza de type 2
EP0979101B1 (de) 1996-07-03 2010-10-27 Merial, Inc. Rekombinanter hunde-adenovirus 2 (cav2), welcher exogene dna enthält
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
BR0210539A (pt) 2001-06-19 2005-04-26 Us Gov Health & Human Serv Processos de seleção e uso de vacinas de vetor antiartrópode
MXPA05003049A (es) 2002-09-19 2005-11-17 Us Gov Health & Human Serv Polipeptidos de phlebotomus ariasi, polipeptidos de phlebotomus perniciosus y metodos de uso.
MXPA05004714A (es) 2002-10-29 2006-03-17 Us Gov Health & Human Serv Polipeptidos de lutzomyia longipalpis y metodos de uso.

Also Published As

Publication number Publication date
US20160279211A1 (en) 2016-09-29
US8628780B2 (en) 2014-01-14
AU2003287267A8 (en) 2004-05-25
EP1572968B1 (de) 2009-04-22
DE60327366D1 (de) 2009-06-04
WO2004039958A2 (en) 2004-05-13
US9382302B2 (en) 2016-07-05
EP1572968A2 (de) 2005-09-14
US9884100B2 (en) 2018-02-06
BR0315872A (pt) 2006-07-18
JP2010142226A (ja) 2010-07-01
AU2003287267A1 (en) 2004-05-25
US20180147269A1 (en) 2018-05-31
US9120867B2 (en) 2015-09-01
US20090117139A1 (en) 2009-05-07
EP2085467B1 (de) 2013-12-11
US7485306B2 (en) 2009-02-03
JP2006516187A (ja) 2006-06-29
EP1572968A4 (de) 2006-07-19
ES2447843T3 (es) 2014-03-13
EP2085467A2 (de) 2009-08-05
WO2004039958A3 (en) 2005-12-08
US10314900B2 (en) 2019-06-11
US20140093531A1 (en) 2014-04-03
US20150315254A1 (en) 2015-11-05
EP2085467A3 (de) 2009-10-14
US20060051364A1 (en) 2006-03-09
MXPA05004714A (es) 2006-03-17

Similar Documents

Publication Publication Date Title
DE60043158D1 (de) Heteroklitische analoga von klasse-i epitopen
DE60327366D1 (de) Lutzomyia longipalpis-polypeptide und verwendungsverfahren
CY1110961T1 (el) Πρωτεϊνη παρομοια προς νευροενδοκρινικη-ειδικη πρωτεϊνη και κωδικοποιουσα cdna
ATE405647T1 (de) Rekombinantes gelatin in impstoffen
DE69410604D1 (de) Biometrische identifizierung von personen
DE69836588D1 (de) Tuberkulose impfstoff
DE60209182D1 (de) Erzeugung von Rufdetailaufzeichnungen
EP1579532A4 (de) Tragbare elektrische energiequelle
FI960727L (fi) Neurokiniiniantagonisteina käyttökelpoiset heterosyklit
DK1370674T3 (da) Enzymer med alfa-amylase-aktivitet samt fremgangsmåder til anvendelse deraf
FR2836297B1 (fr) Bougie d'allumage
ATE454403T1 (de) Menschliche koagulationsfaktor vii polypeptide
EP1026949A4 (de) Protein der äusseren membran von ehrlichia canis und erlichia chaffeensis
ES2164684T3 (es) Uso de antagonistas de taquiquininas en el tratamiento de emesis.
ATE302789T1 (de) Zellkernmatrixproteine
DE59906754D1 (de) Ortsveränderliche Fluggastbrücke
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
NO872987D0 (no) Broennhodeutstyr.
FR2843244B1 (fr) Bougie d'allumage
MXPA05003049A (es) Polipeptidos de phlebotomus ariasi, polipeptidos de phlebotomus perniciosus y metodos de uso.
ATE269134T1 (de) Puzzle
CY1108280T1 (el) Basb205 πολυπεπτιδια και πολυνουκλεοτιδια που τα κωδικοποιουν
EP1394407A4 (de) Energieerzeuger der pendelart
ATE428027T1 (de) Beleuchtungseinrichtung
ATE367438T1 (de) Verfahren zur steigerung der expression von menschlichen tnf-rezeptor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties